RPE: A Potential Drug Target for Various Diseases (G6120)

Target Name: RPE

NCBI ID: G6120

Content of Review Report on RPE Target / Biomarker

RPE

RPE: A Potential Drug Target for Various Diseases

Ribulose-phosphate 3-epimerase (RPE) is a gene that encodes a protein involved in the metabolism of carbohydrates, specifically glucose. RPE is a key enzyme in the glycolytic pathway, a critical pathway for cellular energy metabolism. Mutations in the RPE gene have been linked to various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. As a result, RPE has emerged as a promising drug target for the treatment of various diseases.

The RPE gene is located on chromosome 16 and encodes a protein with 21 amino acid residues. The protein has a molecular weight of 34 kDa and a calculated pI of 6.5. RPE is expressed in most tissues of the body and is primarily localized to the cytoplasm. The cytoplasm is the fluid inside the cell that contains the cell's organelles, including the mitochondria, ribosomes, and endoplasmic reticulum.

RPE is involved in the metabolism of glucose, which is the body's primary energy source. The glucose molecule is broken down into two

Protein Name: Ribulose-5-phosphate-3-epimerase

Functions: Catalyzes the reversible epimerization of D-ribulose 5-phosphate to D-xylulose 5-phosphate

The "RPE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets